Silo Pharma, Inc. (SILO)
USD 0.75
(-3.85%)
USD 0.75
(-3.85%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.62 Million USD | -7.85% |
| 2022 | -3.9 Million USD | -23.63% |
| 2021 | 4.18 Million USD | -20.83% |
| 2020 | -2.39 Million USD | -165.23% |
| 2019 | -930.4 Thousand USD | -1360.66% |
| 2018 | -951.91 Thousand USD | 106.11% |
| 2017 | - USD | -459.73% |
| 2016 | - USD | 1410.71% |
| 2015 | -217.17 Thousand USD | 79.5% |
| 2014 | -248.87 Thousand USD | 31.49% |
| 2013 | -71.98 Thousand USD | -348.42% |
| 2012 | -39.44 Thousand USD | 20.8% |
| 2011 | -49.8 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1 Million USD | -16.27% |
| 2024 Q1 | -879.51 Thousand USD | 23.92% |
| 2023 Q3 | -657.22 Thousand USD | 34.63% |
| 2023 Q4 | -1.16 Million USD | -77.07% |
| 2023 FY | - USD | -7.85% |
| 2023 Q1 | -739.09 Thousand USD | 59.82% |
| 2023 Q2 | -1 Million USD | -36.03% |
| 2022 Q4 | -1.83 Million USD | -101.26% |
| 2022 Q1 | -491.19 Thousand USD | 51.18% |
| 2022 FY | - USD | -23.63% |
| 2022 Q2 | -330.07 Thousand USD | 32.8% |
| 2022 Q3 | -914.08 Thousand USD | -176.93% |
| 2021 Q2 | -556.03 Thousand USD | 43.01% |
| 2021 Q1 | -975.6 Thousand USD | -40.06% |
| 2021 Q4 | -1 Million USD | -103.71% |
| 2021 Q3 | -493.94 Thousand USD | 11.17% |
| 2021 FY | - USD | -20.83% |
| 2020 Q4 | -696.56 Thousand USD | -27.02% |
| 2020 FY | - USD | -165.23% |
| 2020 Q1 | -157.32 Thousand USD | 46.3% |
| 2020 Q2 | -990.75 Thousand USD | -529.75% |
| 2020 Q3 | -548.4 Thousand USD | 44.65% |
| 2019 Q3 | -245.42 Thousand USD | -30.32% |
| 2019 FY | - USD | -1360.66% |
| 2019 Q1 | -175.56 Thousand USD | -215.73% |
| 2019 Q2 | -188.33 Thousand USD | -7.27% |
| 2019 Q4 | -292.95 Thousand USD | -19.36% |
| 2018 Q3 | 35.83 Thousand USD | -78.11% |
| 2018 Q1 | -287.24 Thousand USD | 40.49% |
| 2018 FY | - USD | 106.11% |
| 2018 Q4 | 151.69 Thousand USD | 323.33% |
| 2018 Q2 | 163.73 Thousand USD | 157.0% |
| 2017 Q1 | -1.02 Million USD | -11029.31% |
| 2017 FY | - USD | -459.73% |
| 2017 Q2 | -66.14 Thousand USD | 93.52% |
| 2017 Q3 | 335.83 Thousand USD | 607.75% |
| 2017 Q4 | -482.64 Thousand USD | -243.71% |
| 2016 Q1 | -114.13 Thousand USD | -7.3% |
| 2016 Q4 | 9346.00 USD | -96.51% |
| 2016 Q3 | 267.82 Thousand USD | 64.69% |
| 2016 Q2 | 162.62 Thousand USD | 242.48% |
| 2016 FY | - USD | 1410.71% |
| 2015 Q1 | -151.73 Thousand USD | -287.69% |
| 2015 FY | - USD | 79.5% |
| 2015 Q4 | -106.37 Thousand USD | -127.07% |
| 2015 Q3 | 392.96 Thousand USD | 346.05% |
| 2015 Q2 | -159.71 Thousand USD | -5.26% |
| 2014 Q2 | 372.72 Thousand USD | 175.05% |
| 2014 Q4 | -39.13 Thousand USD | -192.69% |
| 2014 FY | - USD | 31.49% |
| 2014 Q3 | 42.22 Thousand USD | -88.67% |
| 2014 Q1 | -496.66 Thousand USD | -2278.31% |
| 2013 Q2 | -22.47 Thousand USD | 1.77% |
| 2013 FY | - USD | -348.42% |
| 2013 Q4 | -20.88 Thousand USD | -263.56% |
| 2013 Q3 | -5744.00 USD | 74.44% |
| 2013 Q1 | -22.88 Thousand USD | -87.73% |
| 2012 Q1 | -13.03 Thousand USD | -105.89% |
| 2012 Q2 | -5668.00 USD | 56.53% |
| 2012 Q3 | -8550.00 USD | -50.85% |
| 2012 Q4 | -12.18 Thousand USD | -42.56% |
| 2012 FY | - USD | 20.8% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | -6333.00 USD | 64.26% |
| 2011 Q3 | -17.71 Thousand USD | -27.91% |
| 2011 Q2 | -13.85 Thousand USD | -16.43% |
| 2011 Q1 | -11.89 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Absci Corporation | -95.45 Million USD | 96.201% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 98.084% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 98.596% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 63.323% |
| Apollomics, Inc. | -171.74 Million USD | 97.889% |
| 180 Life Sciences Corp. | -22.13 Million USD | 83.617% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 88.435% |
| Bicycle Therapeutics plc | -183.4 Million USD | 98.023% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 95.153% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 97.808% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 83.164% |
| Chimerix, Inc. | -92.97 Million USD | 96.1% |
| CRISPR Therapeutics AG | -202.7 Million USD | 98.211% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 115.383% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 94.745% |
| Fortress Biotech, Inc. | -133.64 Million USD | 97.287% |
| Fortress Biotech, Inc. | -133.64 Million USD | 97.287% |
| Gritstone bio, Inc. | -126.86 Million USD | 97.142% |
| Allakos Inc. | -189.91 Million USD | 98.091% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 92.52% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 96.918% |
| Cytokinetics, Incorporated | -456.68 Million USD | 99.206% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 96.174% |
| Innoviva, Inc. | 248.96 Million USD | 101.457% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -2267.769% |
| NLS Pharmaceutics AG | -11.79 Million USD | 69.258% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 97.119% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -28043.151% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 96.454% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 95.901% |
| ImmuCell Corporation | -2.5 Million USD | -44.812% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 97.22% |
| Incyte Corporation | 919.42 Million USD | 100.394% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 97.219% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 43.24% |
| Mustang Bio, Inc. | -48.06 Million USD | 92.455% |
| MiMedx Group, Inc. | 40.51 Million USD | 108.95% |
| MEI Pharma, Inc. | 26.38 Million USD | 113.746% |
| MacroGenics, Inc. | 2.01 Million USD | 279.783% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 945.194% |
| Mereo BioPharma Group plc | -26.05 Million USD | 86.083% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 69.249% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 97.111% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 100.509% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 83.283% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 77.165% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 65.897% |
| NextCure, Inc. | -59.03 Million USD | 93.858% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 92.92% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 63.621% |
| Onconetix, Inc. | -36.7 Million USD | 90.121% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 262.247% |
| Opthea Limited | -200.01 Million USD | 98.187% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 93.824% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -31.787% |
| PDS Biotechnology Corporation | -40.08 Million USD | 90.954% |
| Precigen, Inc. | -89.22 Million USD | 95.936% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 84.069% |
| Prime Medicine, Inc. | -193.75 Million USD | 98.128% |
| PureTech Health plc | -11.62 Million USD | 68.812% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 98.468% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.078% |
| Replimune Group, Inc. | -230.19 Million USD | 98.425% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -3708.728% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 78.645% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 79.825% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 99.158% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 84.961% |
| Sesen Bio, Inc. | -50.84 Million USD | 92.867% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 95.852% |
| Solid Biosciences Inc. | -93.43 Million USD | 96.119% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 98.423% |
| SciSparc Ltd. | -5.28 Million USD | 31.348% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 94.661% |
| TG Therapeutics, Inc. | 26.1 Million USD | 113.894% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 96.822% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 49.39% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 98.889% |
| UroGen Pharma Ltd. | -63.83 Million USD | 94.319% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 94.17% |
| XOMA Corporation | -39.36 Million USD | 90.788% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 98.684% |
| AbCellera Biologics Inc. | -192.15 Million USD | 98.113% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 93.611% |
| Cassava Sciences, Inc. | -95.68 Million USD | 96.21% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 91.84% |
| Precision BioSciences, Inc. | -32.04 Million USD | 88.683% |
| Dyadic International, Inc. | -8.22 Million USD | 55.938% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 64.047% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -1146.122% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 87.606% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 97.04% |
| IGM Biosciences, Inc. | -253.35 Million USD | 98.569% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 96.614% |
| Acelyrin, Inc. | -381.52 Million USD | 99.05% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 92.83% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 103.565% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 81.789% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 84.995% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 97.693% |
| Senti Biosciences, Inc. | -61.33 Million USD | 94.088% |
| Mesoblast Limited | -61.33 Million USD | 94.087% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 97.468% |
| ChromaDex Corporation | -3.89 Million USD | 6.877% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 24.319% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 47.201% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 1566.82% |
| Seer, Inc. | -97.88 Million USD | 96.295% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 84.722% |
| Novavax, Inc. | -487.39 Million USD | 99.256% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -61.185% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 97.895% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 93.046% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 98.39% |
| Celcuity Inc. | -58.3 Million USD | 93.781% |
| ContextLogic Inc. | -324 Million USD | 98.881% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 97.72% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 95.312% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 100.25% |
| Amarin Corporation plc | -50.9 Million USD | 92.876% |
| AnaptysBio, Inc. | -143.16 Million USD | 97.467% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 87.192% |
| Aptorum Group Limited | -9.59 Million USD | 62.223% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 98.457% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 97.936% |
| Ardelyx, Inc. | -55.35 Million USD | 93.449% |
| Celularity Inc. | -183.94 Million USD | 98.029% |
| Omeros Corporation | -163.61 Million USD | 97.784% |
| Humacyte, Inc. | -96.45 Million USD | 96.241% |
| Immunocore Holdings plc | -59.64 Million USD | 93.921% |
| IO Biotech, Inc. | -91.22 Million USD | 96.025% |
| GT Biopharma, Inc. | 5.97 Million USD | 160.649% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 95.048% |
| Summit Therapeutics Inc. | 1 Million USD | 462.259% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 88.266% |
| Pulmatrix, Inc. | -12.64 Million USD | 71.325% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 99.284% |
| Evogene Ltd. | -23.2 Million USD | 84.372% |
| CorMedix Inc. | -48.88 Million USD | 92.582% |
| BioLineRx Ltd. | -57.06 Million USD | 93.645% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 88.826% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 88.204% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 98.902% |
| scPharmaceuticals Inc. | -46.06 Million USD | 92.127% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 96.658% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 103.348% |
| NLS Pharmaceutics AG | -11.79 Million USD | 69.258% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 84.961% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 97.56% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 73.44% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 85.79% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 96.771% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 95.59% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 93.68% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 79.639% |
| Daré Bioscience, Inc. | -30.7 Million USD | 88.189% |
| bluebird bio, Inc. | -167.16 Million USD | 97.831% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 101.169% |
| DBV Technologies S.A. | -85.98 Million USD | 95.783% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 98.447% |
| Galecto, Inc. | -37.51 Million USD | 90.335% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 89.139% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 92.344% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 98.246% |
| GlycoMimetics, Inc. | -39.12 Million USD | 90.731% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 98.406% |
| ADMA Biologics, Inc. | 5.12 Million USD | 170.824% |
| Clene Inc. | -43.24 Million USD | 91.614% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 98.79% |
| Aptose Biosciences Inc. | -52.26 Million USD | 93.062% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 96.634% |
| Soligenix, Inc. | -7.85 Million USD | 53.823% |
| Century Therapeutics, Inc. | -121.2 Million USD | 97.008% |
| Kura Oncology, Inc. | -164.95 Million USD | 97.802% |
| Surrozen, Inc. | -41.13 Million USD | 91.184% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 95.473% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -278.622% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 15.846% |
| Autolus Therapeutics plc | -156.77 Million USD | 97.687% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 95.717% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 81.809% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 96.778% |
| GRI Bio, Inc. | -10.89 Million USD | 66.726% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 19.698% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 94.894% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 96.506% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 90.491% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 76.347% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 55.92% |
| Jaguar Health, Inc. | -33.13 Million USD | 89.055% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 76.967% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 93.621% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 84.274% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 98.637% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 98.13% |
| Verastem, Inc. | -83.16 Million USD | 95.64% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 97.708% |
| Histogen Inc. | -10.5 Million USD | 65.474% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 74.606% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 94.654% |
| Surrozen, Inc. | -41.13 Million USD | 91.184% |
| Organovo Holdings, Inc. | -14.8 Million USD | 75.508% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 113171.843% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 56.51% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 97.816% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 92.638% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 75.914% |
| Kronos Bio, Inc. | -121.83 Million USD | 97.024% |
| Turnstone Biologics Corp. | -56.23 Million USD | 93.552% |
| Synaptogenix, Inc. | -8.3 Million USD | 56.35% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 76.36% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -1029.662% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 94.248% |
| Exelixis, Inc. | 196.6 Million USD | 101.844% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 97.436% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 99.268% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 94.42% |
| ESSA Pharma Inc. | -26.45 Million USD | 86.293% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 9.343% |
| Avid Bioservices, Inc. | -11.48 Million USD | 68.416% |
| Insmed Incorporated | -654.73 Million USD | 99.446% |
| MediWound Ltd. | -4.89 Million USD | 25.89% |
| OmniAb, Inc. | -49.73 Million USD | 92.708% |
| Alector, Inc. | -142.89 Million USD | 97.462% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 95.756% |
| Zai Lab Limited | -366.57 Million USD | 99.011% |
| AlloVir, Inc. | -190.14 Million USD | 98.093% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 98.752% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 96.696% |
| Aura Biosciences, Inc. | -83.69 Million USD | 95.667% |
| Immunic, Inc. | -99.11 Million USD | 96.341% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 97.246% |
| Veracyte, Inc. | -49.4 Million USD | 92.661% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 48.666% |
| FibroGen, Inc. | -261.4 Million USD | 98.613% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 67.452% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 104.177% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 48.207% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 80.626% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 85.736% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 109.091% |
| Fortrea Holdings Inc. | 167.3 Million USD | 102.167% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 97.3% |
| XBiotech Inc. | -35.76 Million USD | 89.861% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 94.42% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 97.617% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 785.485% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 94.443% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 96.528% |
| Agenus Inc. | -145.92 Million USD | 97.515% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 85.875% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 91.127% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 99.298% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 93.527% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 96.883% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 83.643% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 97.03% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 34.374% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 85.719% |
| Lantern Pharma Inc. | -15.78 Million USD | 77.03% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| Ainos, Inc. | -8.77 Million USD | 58.667% |
| Pluri Inc. | -20.22 Million USD | 82.071% |
| Prothena Corporation plc | -190.1 Million USD | 98.093% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 97.171% |
| Rallybio Corporation | -72.37 Million USD | 94.99% |
| Kodiak Sciences Inc. | -259.02 Million USD | 98.6% |
| Cue Biopharma, Inc. | -46.05 Million USD | 92.126% |
| MeiraGTx Holdings plc | -57.05 Million USD | 93.644% |
| Annexon, Inc. | -141.57 Million USD | 97.439% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 94.351% |
| Moderna, Inc. | -3.28 Billion USD | 99.89% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 81.281% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 85.117% |
| Blueprint Medicines Corporation | -474.61 Million USD | 99.236% |
| Immix Biopharma, Inc. | -16.13 Million USD | 77.527% |
| CalciMedica, Inc. | -34.18 Million USD | 89.394% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 97.355% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 97.847% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 93.832% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 98.563% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 89.0% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 96.417% |
| Nutriband Inc. | -5.12 Million USD | 29.2% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 91.62% |
| Vor Biopharma Inc. | -114.37 Million USD | 96.829% |
| Roivant Sciences Ltd. | -996.51 Million USD | 99.636% |
| Alkermes plc | 495.04 Million USD | 100.732% |
| ProKidney Corp. | -147.66 Million USD | 97.544% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 94.381% |
| Arcellx, Inc. | -64.14 Million USD | 94.347% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 99.359% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 96.755% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -1695.155% |
| Atai Life Sciences N.V. | -36.31 Million USD | 90.013% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 95.44% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 95.54% |
| MediciNova, Inc. | -9.87 Million USD | 63.297% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 97.121% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -136.976% |
| GeoVax Labs, Inc. | -26.66 Million USD | 86.403% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 98.388% |
| Biomea Fusion, Inc. | -124.62 Million USD | 97.09% |
| RenovoRx, Inc. | -11.39 Million USD | 68.163% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 98.095% |
| Geron Corporation | -174.78 Million USD | 97.925% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 87.923% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 96.615% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 98.447% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 84.134% |
| Royalty Pharma plc | 1.88 Billion USD | 100.192% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 98.255% |
| Imunon, Inc. | -19.87 Million USD | 81.758% |
| BioAtla, Inc. | -122.24 Million USD | 97.034% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 98.792% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 91.251% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 97.817% |
| Structure Therapeutics Inc. | -102.45 Million USD | 96.461% |
| 89bio, Inc. | -134.46 Million USD | 97.303% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 96.347% |
| aTyr Pharma, Inc. | -52.17 Million USD | 93.05% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 95.674% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 98.454% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 54.911% |
| Akari Therapeutics, Plc | -16.8 Million USD | 78.418% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 2021.621% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 100.802% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 97.782% |
| Liquidia Corporation | -70.05 Million USD | 94.823% |
| Entera Bio Ltd. | -8.8 Million USD | 58.812% |
| GH Research PLC | -41.15 Million USD | 91.188% |
| Vericel Corporation | 2.86 Million USD | 226.614% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 94.892% |
| Xencor, Inc. | -125.87 Million USD | 97.119% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -154.196% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 76.347% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 82.011% |
| Vaxcyte, Inc. | -464.88 Million USD | 99.22% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 98.277% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 66.86% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 43.24% |
| Portage Biotech Inc. | -18.19 Million USD | 80.075% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -136.976% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 96.533% |
| OncoCyte Corporation | -23.12 Million USD | 84.318% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 67.911% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 68.349% |
| Purple Biotech Ltd. | -22.22 Million USD | 83.684% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 87.398% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 87.48% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 97.847% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 43.429% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 87.709% |
| United Therapeutics Corporation | 1.38 Billion USD | 100.261% |
| HilleVax, Inc. | -132.46 Million USD | 97.263% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 40.715% |
| Pharming Group N.V. | 9.87 Million USD | 136.714% |
| Tharimmune, Inc. | -9.3 Million USD | 61.019% |
| Genprex, Inc. | -31.06 Million USD | 88.325% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 95.682% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 98.066% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 95.38% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -374.635% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 2502.994% |
| OKYO Pharma Limited | -15.74 Thousand USD | -22929.62% |
| Savara Inc. | -59.13 Million USD | 93.868% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 82.012% |
| Curis, Inc. | -45.13 Million USD | 91.967% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 76.129% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 86.436% |
| BeiGene, Ltd. | -1.12 Billion USD | 99.678% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 95.986% |
| Erasca, Inc. | -121.31 Million USD | 97.011% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 19.395% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 19.395% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 91.49% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 35.796% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 93.941% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 97.392% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 98.239% |
| Adicet Bio, Inc. | -136.53 Million USD | 97.344% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 96.062% |
| Aditxt, Inc. | -25.45 Million USD | 85.756% |
| Adagene Inc. | -14.95 Million USD | 75.746% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 50.394% |
| Quantum-Si incorporated | -91.8 Million USD | 96.05% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 102.868% |
| Compugen Ltd. | -12.51 Million USD | 71.027% |
| Generation Bio Co. | -133.3 Million USD | 97.28% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 95.633% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 95.785% |
| Invivyd, Inc. | -196.61 Million USD | 98.156% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 99.031% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 60.903% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 113.354% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 64.743% |
| 2seventy bio, Inc. | -206.41 Million USD | 98.243% |
| Instil Bio, Inc. | -146.12 Million USD | 97.518% |
| Capricor Therapeutics, Inc. | -23 Million USD | 84.24% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 15.084% |
| GeoVax Labs, Inc. | -26.66 Million USD | 86.403% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 90.127% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 173.85% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 97.711% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 99.47% |
| Evaxion Biotech A/S | -21.4 Million USD | 83.057% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 94.54% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 98.334% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 95.444% |
| Cingulate Inc. | -22.95 Million USD | 84.201% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 51.398% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 90.274% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 93.788% |
| Clearmind Medicine Inc. | -8.71 Million USD | 58.37% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 95.122% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -48.529% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 96.404% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 99.046% |
| ImmunityBio, Inc. | -436.18 Million USD | 99.169% |
| Korro Bio, Inc. | -80.9 Million USD | 95.518% |
| Kineta, Inc. | -15.71 Million USD | 76.924% |
| BioVie Inc. | -31.95 Million USD | 88.65% |
| Codexis, Inc. | -49.28 Million USD | 92.642% |
| Celularity Inc. | -183.94 Million USD | 98.029% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 76.774% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 98.363% |
| Virax Biolabs Group Limited | -6.6 Million USD | 45.133% |
| Cibus, Inc. | -314.58 Million USD | 98.847% |
| IN8bio, Inc. | -28.5 Million USD | 87.278% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 96.78% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 87.028% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 98.423% |
| Eyenovia, Inc. | -24.1 Million USD | 84.957% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 108.097% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -1019.202% |
| Elevation Oncology, Inc. | -41.46 Million USD | 91.255% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 95.087% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 91.944% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 97.063% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 88.258% |
| Moolec Science SA | -52.07 Million USD | 93.037% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 92.973% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 91.028% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 96.968% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 92.519% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 61.11% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 82.516% |
| Humacyte, Inc. | -96.45 Million USD | 96.241% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 95.403% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 189.492% |
| Genelux Corporation | -24.16 Million USD | 84.994% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 89.272% |
| Notable Labs, Ltd. | -14.4 Million USD | 74.818% |
| Immunovant, Inc. | -269.97 Million USD | 98.657% |
| Quantum-Si incorporated | -91.8 Million USD | 96.05% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 81.219% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 96.445% |
| Acasti Pharma Inc. | -11.3 Million USD | 67.912% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 83.705% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 90.207% |
| PepGen Inc. | -83.58 Million USD | 95.661% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 84.163% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 24.006% |
| Immuneering Corporation | -58.06 Million USD | 93.754% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 113171.843% |
| Belite Bio, Inc | -31.52 Million USD | 88.499% |
| XOMA Corporation | -39.36 Million USD | 90.788% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 94.624% |
| Bionomics Limited | -9.83 Million USD | 63.137% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 89.521% |
| uniQure N.V. | -253.1 Million USD | 98.567% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 50.394% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 97.2% |
| Forte Biosciences, Inc. | -32.47 Million USD | 88.835% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 54.957% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 87.15% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -1019.202% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 67.452% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 77.195% |
| Altimmune, Inc. | -87.93 Million USD | 95.876% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 97.034% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 89.521% |
| Peak Bio, Inc. | -1356.23 USD | -267274.56% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 92.538% |
| Benitec Biopharma Inc. | -22.49 Million USD | 83.876% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 98.503% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 87.296% |
| Zura Bio Limited | -60.56 Million USD | 94.012% |
| PolyPid Ltd. | -20.26 Million USD | 82.104% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 87.296% |
| argenx SE | -216.02 Million USD | 98.321% |
| Immunome, Inc. | -28.27 Million USD | 87.173% |
| Verona Pharma plc | -52.46 Million USD | 93.089% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 96.174% |
| Shattuck Labs, Inc. | -87.61 Million USD | 95.861% |
| CervoMed Inc. | -2.17 Million USD | -66.962% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 71.431% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 92.473% |
| Moolec Science SA | -52.07 Million USD | 93.037% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 78.844% |
| Design Therapeutics, Inc. | -66.32 Million USD | 94.533% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 95.522% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 90.394% |
| Achilles Therapeutics plc | -70.44 Million USD | 94.852% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -48.529% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 93.458% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 92.826% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 94.445% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 93.298% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 92.009% |
| Beam Therapeutics Inc. | -156.47 Million USD | 97.683% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 97.343% |
| AEON Biopharma, Inc. | -48.36 Million USD | 92.502% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 94.452% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 95.574% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 70.638% |
| NeurAxis, Inc. | -6.66 Million USD | 45.589% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 99.152% |
| Lumos Pharma, Inc. | -36.57 Million USD | 90.084% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 162.207% |
| Palisade Bio, Inc. | -12.28 Million USD | 70.473% |
| Nutriband Inc. | -5.12 Million USD | 29.2% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 96.553% |
| Neurogene Inc. | -52.28 Million USD | 93.065% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 56.81% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 96.102% |
| Athira Pharma, Inc. | -116.7 Million USD | 96.893% |
| HCW Biologics Inc. | -23.57 Million USD | 84.619% |
| XOMA Corporation | -39.36 Million USD | 90.788% |
| Nektar Therapeutics | -243.1 Million USD | 98.508% |
| Arvinas, Inc. | -394.8 Million USD | 99.082% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 2021.621% |
| Merus N.V. | -149.2 Million USD | 97.57% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 96.121% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 88.4% |
| Rezolute, Inc. | -68.42 Million USD | 94.7% |
| Clene Inc. | -43.24 Million USD | 91.614% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 76.487% |
| BeyondSpring Inc. | -21.54 Million USD | 83.165% |
| Synlogic, Inc. | -55.16 Million USD | 93.426% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 69.989% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 65.925% |
| Peak Bio, Inc. | -1356.23 USD | -267274.56% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 88.83% |
| Krystal Biotech, Inc. | 17.9 Million USD | 120.254% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 96.938% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 98.938% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 21.279% |
| MannKind Corporation | 15.12 Million USD | 123.969% |
| Ikena Oncology, Inc. | -74.39 Million USD | 95.126% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 71.205% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 117.839% |
| Gossamer Bio, Inc. | -172.15 Million USD | 97.894% |
| CohBar, Inc. | -12.06 Million USD | 69.946% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 85.785% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 87.923% |
| Legend Biotech Corporation | -477.87 Million USD | 99.241% |
| Mural Oncology plc | -192.72 Million USD | 98.118% |
| Disc Medicine, Inc. | -91.02 Million USD | 96.016% |
| Champions Oncology, Inc. | -5.05 Million USD | 28.251% |
| REGENXBIO Inc. | -239.46 Million USD | 98.486% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 66.168% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 93.496% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 90.646% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 96.785% |
| Vaxart, Inc. | -74.72 Million USD | 95.147% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 89.701% |
| Cellectis S.A. | -98.09 Million USD | 96.303% |
| Longeveron Inc. | -20.06 Million USD | 81.923% |
| Repare Therapeutics Inc. | -114.27 Million USD | 96.827% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 99.174% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 95.153% |
| Revolution Medicines, Inc. | -430.58 Million USD | 99.158% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 42.34% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 88.222% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 95.138% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 173.959% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 66.929% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.079% |
| Denali Therapeutics Inc. | -179.97 Million USD | 97.985% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -3708.728% |
| Veru Inc. | -89.97 Million USD | 95.97% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 86.509% |
| Cingulate Inc. | -22.95 Million USD | 84.201% |
| Passage Bio, Inc. | -98.34 Million USD | 96.313% |
| Context Therapeutics Inc. | -25.06 Million USD | 85.53% |
| Exicure, Inc. | -15.53 Million USD | 76.664% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 98.24% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 90.193% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 39.184% |
| Nuvalent, Inc. | -149.49 Million USD | 97.574% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 55.41% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 95.778% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 87.984% |
| OmniAb, Inc. | -49.73 Million USD | 92.708% |
| Anew Medical, Inc. | -1.3 Million USD | -178.759% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 70.671% |
| Lipocine Inc. | -16.32 Million USD | 77.784% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 94.561% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 95.12% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 90.491% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 90.705% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 83.653% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 99.335% |
| Ocugen, Inc. | -64.82 Million USD | 94.406% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 96.083% |
| Q32 Bio Inc. | -86.5 Million USD | 95.808% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 78.577% |
| Alumis Inc. Common Stock | -156.89 Million USD | 97.689% |
| Equillium, Inc. | -12.13 Million USD | 70.125% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 93.798% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 54.118% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 80.774% |
| Dominari Holdings Inc. | -22.44 Million USD | 83.84% |
| Edesa Biotech, Inc. | -8.19 Million USD | 55.725% |
| vTv Therapeutics Inc. | -25.41 Million USD | 85.73% |
| Bio-Techne Corporation | 326.66 Million USD | 101.11% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 99.058% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 101.676% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 97.234% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 90.312% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 97.6% |
| Nkarta, Inc. | -120.48 Million USD | 96.99% |
| BioCardia, Inc. | -11.56 Million USD | 68.631% |
| Iterum Therapeutics plc | -34.58 Million USD | 89.514% |